title: [Lipoprotein changes during hormonal treatment of endometriosis with lynestrenol and danazol].
abstract: The Lipoprotein profile of 24 patients with endometriosis was determined before, during and after the treatment with the two steroid hormones Lynestrenol (10 mg/day) and Danazol (600-800 mg/day). The total cholesterol triglycerides, beta-, prebeta-, and Alphalipo -protein bound to cholesterol were determined. Both hormones cause a marked lowering of the Alpha-Lp-cholesterin. In addition, the beta-LP-cholesterin was elevated and the beta-alpha-LP-ratio was elevated. In the dosage used by us, Lynestrenol showed less effect on the Lipoprotein profile. Danazol caused changed in the beta- and alpha-lipoprotein pattern of highly pathological atherogenic types. The total cholesterol was not influenced. Since women in the fertile age group will suffer a higher risk of arteriosclerosis from an elevation of the beta-LP-cholesterin, the treatment with Danazol calls for a sophisticated monitoring of the lipid metabolism and care in the indication for long term treatment with Danazol or with Lynestrenol.
mesh_terms: D000328:Adult; D001161:Arteriosclerosis / Q000139:chemically induced; D003327:Coronary Disease / Q000097:blood; D003613:Danazol / Q000009:adverse effects / Q000494:pharmacology*; D004715:Endometriosis / Q000188:drug therapy*; D005260:Female; D006801:Humans; D008074:Lipoproteins / Q000097:blood*; D008234:Lynestrenol / Q000009:adverse effects / Q000494:pharmacology*; D008297:Male; D008875:Middle Aged; D011245:Pregnadienes / Q000494:pharmacology*; D014594:Uterine Neoplasms / Q000188:drug therapy*
chemical_list: D008074:Lipoproteins; D011245:Pregnadienes; D003613:Danazol; D008234:Lynestrenol
vernacular_title: Lipoproteinveränderungen unter Lynestrenol und Danazol in der hormonellen Behandlung der Endometriose.